CurrentBlue Cross Blue Shield - MassachusettsPolicy 134

Signal-averaged electrocardiography (SAECG) coverage policy

Policy governing coverage and use of signal-averaged ECG (SAECG) for Blue Cross Blue Shield - Massachusetts members, describing investigational status and prior authorization requirements where applicable.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySignal-averaged electrocardiography (SAECG) coverage policy

Policy CodePolicy 134

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization when SAECG is performed inpatient; outpatient authorization may vary by product.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1Investigational CPT

InvestigationalCoverage Stance

Precert required (inpatient)Authorization

2023Last Review

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Investigational status: Signal-averaged ECG (SAECG) is considered investigational for all indications including cardiomyopathy, post-myocardial infarction risk stratification, syncope, detection of acute transplant rejection, assessment after arrhythmia surgery, evaluation of antiarrhythmic therapy efficacy, and assessment after interventions to restore coronary blood flow.

This investigational determination applies to commercial members as stated.

Outpatient signal-averaged electrocardiography (SAECG) is not a covered service for Commercial PPO, Indemnity, and Medicare PPO BlueSM members when performed in the outpatient setting. Precertification/preauthorization is required when the procedure is performed inpatient; outpatient prior authorization requirements vary by product and are noted in the policy.

Signal-averaged ECG (SAECG) has shown only modest ability to risk-stratify patients for ventricular arrhythmias and has not been used to place patients into clinically actionable risk categories. Randomized trials that used SAECG to select high-risk patients did not demonstrate outcome benefits from the treatments studied. For a range of diagnostic indications the evidence is insufficient to show clinical utility. Therefore, SAECG has not demonstrated improvements in health outcomes and is considered investigational for all indications for commercial members.

Provider Actions & Billing Requirements

Prior Authorization

Prior Authorization Required

Precertification / prior authorization is required for inpatient services described in this policy. Failure to obtain the required precertification may result in denial of payment or other administrative actions.

Applies to all product types when the procedure is performed inpatient

Note

Provider Actions

Providers must obtain precertification for inpatient admissions and follow payer-specific authorization procedures before scheduling the service. Contact Blue Cross Blue Shield - Massachusetts for authorization submission details and required documentation.

Confirm authorization number is included on the claim
Notify the payer promptly of any changes to the service or admission status

Documentation Required

Coding and Documentation Guidance

Report services using current, industry-standard procedure, revenue, and diagnosis codes, and include applicable modifiers. Use the most up-to-date CPT/HCPCS/ICD-10 codes when submitting claims.

Include authorization/precertification number on claims when required
Use accurate ICD-10 diagnosis codes reflecting the reason for the service

Denial Risk

Investigational — Not Covered for Commercial Members

Signal-averaged ECG (SAECG) is considered investigational for Commercial Members (Managed Care, PPO, Indemnity) and Medicare Advantage members. Investigational services are not covered for commercial members and may be denied.

SAECG is investigational for Commercial Managed Care (HMO, POS), PPO, Indemnity, and Medicare Advantage members
Investigational services are not covered for commercial members

Denial Risk

Precertification Required (Inpatient) — Risk of Denial

Lack of required precertification for inpatient services may lead to claim denial or retrospective review. Verify authorization requirements prior to service to avoid administrative or financial liability.

Denials may be applied if precertification is not obtained for inpatient services
Check member contract benefits to confirm coverage and any product-specific rules

Background

Signal-averaged electrocardiography (SAECG) is a computerized, high-resolution analysis of ECG recordings designed to detect ventricular late potentials (VLPs), small electrical abnormalities that reflect delayed ventricular activation and are associated with risk of ventricular tachyarrhythmias. SAECG has been investigated as a risk marker in conditions such as cardiomyopathy and after myocardial infarction, but available evidence shows only modest predictive ability and has not demonstrated clinically meaningful improvements in patient outcomes.

Definitions

Ventricular late potentials (VLPs) — definition and notes

DefinitionVentricular late potentials (VLPs) are small abnormalities detected by signal-averaged electrocardiography (SAECG) that represent delayed activation of the ventricles.

Clinical significanceVLPs are associated with an increased risk of ventricular tachycardia and have been investigated as a risk factor for arrhythmic events in conditions such as cardiomyopathy and prior myocardial infarction.

Measurement methodDetected by computerized analysis of small segments of a standard ECG using SAECG to identify low-amplitude, late-occurring signals (late potentials).

Therapeutic implicationsIdentification of VLPs may inform consideration of antiarrhythmic drug therapy or implantable cardioverter-defibrillator placement in patients at high risk for ventricular arrhythmias.

LimitationsWhile VLPs can risk-stratify patients, their predictive ability is modest and this policy does not address other risk stratification methods (e.g., T-wave alternans).